FACTORS DETERMINING THE SUCCESSFUL PERFORMANCE OF CYTOREDUCTIVE OPERATIONS IN OVARIAN CANCER PATIENTS


如何引用文章

全文:

详细

The article reviews literature data on attempts to create various prognostic models with the goal of optimizing indications for surgical treatment and achieving optimal cytoreductive operations in patients with a common form of ovarian cancer. The data of various authors on the sensitivity and specificity of X-ray methods of investigation, laparoscopy, tumor markers, etc. are given in the diagnosis of the spreading of ovarian cancer and their prognostic value for planning optimal cytoreductive operations. There have been demonstrated created by different authors prognostic models which use a complex approach to the surgical treatment of ovarian cancer, which in addition to diagnosing the spreading of the tumor process consider the functional state of the patient, concomitant diseases, age, hematological biochemical changes in the blood, etc.

作者简介

Aslan Zagashtokov

N.N. Blokhin National Medical Research Center of Oncology

Email: zagamedik@mail.ru
MD, Postgraduate Student of the Department of Gynecology of the Research Institute of Clinical Oncology; Moscow, 115478, Russian Federation Moscow, 115478, Russian Federation

S. Nikogosyan

N.N. Blokhin National Medical Research Center of Oncology

Moscow, 115478, Russian Federation

N. Levchenco

N.N. Blokhin National Medical Research Center of Oncology

Moscow, 115478, Russian Federation

参考

  1. Elattar A., Bryant A., Winter-Roach B.A., Hatem M., Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst. Rev. 2011; (8): 1-67. CD007565. doi: 10.1002/14651858.CD007565.pub2.
  2. Munnell E.W. The changing prognosis and treatment in cancer of the ovary. A report of 235 patients with primary ovarian carcinoma 1952-1961. Am. J. Obstet. Gynecol. 1968; 100(6): 790-805.
  3. Eisenkop S.M., Spirtos N.M., Friedman R.L., Lin W.C., Pisani A.L., Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol. Oncol. 2003; 90(2): 390-6.
  4. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 2002; 20(5): 1248-59.
  5. Eisenkop S.M., Friedman R.L., Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 1998; 69(2): 103-8.
  6. Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol. Oncol. 1998; 71(3): 431-6.
  7. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T. et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 1994; 170(4): 974-9; discussion 979-80.
  8. Heintz A.P., Hacker N.F., Berek J.S., Rose T.P., Munoz A.K., Lagasse L.D. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet. Gynecol. 1986; 67(6): 783-8.
  9. Hoskins W.J., Bundy B.N., Thigpen J.T., Omura G.A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 1992; 47(2): 159-66.
  10. Chi D.S., Ramirez P.T., Teitcher J.B., Mironov S., Sarasohn D.M. et al. Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less. J. Clin. Oncol. 2007; 25(31): 4946-51.
  11. Nicklin J.L., McGrath S., Tripcony L., Garrett A., Land R. et al. The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes. Aust. N. Z. J. Obstet. Gynaecol. 2017. doi: 10.1111/ajo.12665.
  12. Onnis A., Marchetti M., Padovan P., Castellan L. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur. J. Gynaecol. Oncol. 1996; 17(5): 393-6.
  13. Shah M.M., Estes J.M., Alvarez R.D. No Residual Disease: The New Definition for Optimal Cytoreduction in Ovarian Cancer? Clin. Ovarian & Other Gynecol. Cancer. 2012; 5(2): 45-7.
  14. Angarita A.M., Stone R., Temkin S.M., Levinson K., Fader A.N., Tanner E.J. The Use of «Optimal Cytoreduction» Nomenclature in Ovarian Cancer Literature: Can We Move Toward a More Optimal Classification System? Int. J. Gynecol. Cancer. 2016; 26(8): 1421-7. doi: 10.1097/IGC.0000000000000796.
  15. Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013; 24 (Suppl. 6): vi24-32. doi: 10.1093/annonc/mdt333.
  16. Clinical practice guidelines for the diagnosis and treatment of patients with ovarian cancer, fallopian tube or primary peritoneal cancer. Association of oncologists of Russia. Moscow; 2014. (in Russian) / Клинические рекомендации по диагностике и лечению больных раком яичников, маточной трубы или первичным раком брюшины. Ассоциация онкологов России. М.; 2014.
  17. Son H.M., Kim S.H., Kwon B.R., Kim M.J., Kim C.S., Cho S.H. Preoperative prediction of suboptimal resection in advanced ovarian cancer based on clinical and CT parameters. Acta Radiol. 2017; 58(4): 498-504. doi: 10.1177/0284185116658683.
  18. Bagul K., Vijaykumar D.K., Rajanbabu A., Antony M.A., Ranganathan V. Advanced Primary Epithelial Ovarian and Peritoneal Carcinoma-Does Diagnostic Accuracy of Preoperative CT Scan for Detection of Peritoneal Metastatic Sites Reflect into Prediction of Suboptimal Debulking? A Prospective Study. Indian J. Surg. Oncol. 2017; 8(2): 98-104. doi: 10.1007/s13193-016-0601-6.
  19. Kim H.J., Choi C.H., Lee Y.Y., Kim T.J., Lee J.W., Bae D.S. et al. Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings. Taiwan J. Obstet. Gynecol. 2014; 53(3): 343-7.
  20. Dowdy S.C., Mullany S.A., Brandt K.R., Huppert B.J., Cliby W.A. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer. 2004; 101(2): 346-52.
  21. Axtell A.E., Lee M.H., Bristow R.E., Dowdy S.C., Cliby W.A., Raman S. et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J. Clin. Oncol. 2007; 25(4): 384-9.
  22. Bristow R.E., Duska L.R., Lambrou N.C., Fishman E.K., O’Neill M.J., Trimble E.L. et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000; 89(7): 1532-40.
  23. Ferrandina G., Sallustio G., Fagotti A., Vizzielli G., Paglia A., Cucci E. et al. Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial. Br. J. Cancer. 2009; 101(7): 1066-73.
  24. Suidan R.S., Ramirez P.T., Sarasohn D.M., Teitcher J.B., Iyer R.B., Zhou Q. et al. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol. Oncol. 2017; 145(1): 27-31.
  25. Alessi A., Martinelli F., Padovano B., Serafini G., Lorusso D., Lorenzoni A. et al. FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results. Tumori. 2016; 102(1): 103-7.
  26. Hynninen J., Kemppainen J., Lavonius M., Virtanen J., Matomaki J., Oksa S. et al. A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer. Gynecol. Oncol. 2013; 131(2): 389-94.
  27. Vargas H., Burger I., Goldman D., Micco M., Sosa R., Weber W. et al. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. European radiology. 2015; 25(11): 3348-53.
  28. Ashrafyan L.A., Aslanidi I.P., Mukhortova O.V., Shurupova I.V., Derevyanko E.P., Katunina T.A. et al. Possibilities of positron emission tomography in the diagnosis of primary and recurrent ovarian cancer: a review of the literature. Opukholi zhenskoy reproduktivnoy sistemy. 2012; (1): 75-8. (in Russian)/Ашрафян Л.А., Асланиди И.П., Мухортова О.В., Шурупова И.В., Деревянко Е.П., Катунина Т.А. и др. Возможности позитронно-эмиссионной томографии в диагностике первичного и рецидивного рака яичников: обзор литературы. Опухоли женской репродуктивной системы. 2012; (1): 75-8.
  29. Janco J.M., Glaser G., Kim B., McGree M.E., Weaver A.L., Cliby W.A. et al. Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer. Gynecol. Oncol. 2015; 138(1): 70-7.
  30. Memarzadeh S., Lee S.B., Berek J.S., Farias-Eisner R. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer. 2003; 13(2): 120-4.
  31. Arits A.H., Stoot J.E., Botterweck A.A., Roumen F.J., Voogd A.C. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int. J. Gynecol. Cancer. 2008; 18(4): 621-8.
  32. Alcazar J.L., Miranda D., Unanue A., Novoa E., Aleman S., Madariaga L. CA-125 levels in predicting optimal cytoreductive surgery in patients with advanced epithelial ovarian carcinoma. Int. J. Gynecol. Obstet. 2004; 84(2): 173-4.
  33. Barlow T.S., Przybylski M., Schilder J.M., Moore D.H., Look K.Y. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int. J. Gynecol. Cancer. 2006; 16(2): 496-500.
  34. Savinova A.R., Gataullin I.G. The clinical significance of CA125 in the diagnosis and monitoring of patients with ovarian cancer. Prakticheskaya meditsina. 2016; (1): 45-52. (in Russian)/ Савинова А.Р., Гатауллин И.Г. Клиническое значение СА125 в диагностике и мониторинге больных раком яичников. Практическая медицина. 2016; 1: 45-52.
  35. Paunovic V., Protrka Z., Ardalic D., Paunovic T. Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer. J. BUON. 2017; 22(1): 29-33.
  36. Tang Z., Chang X., Ye X., Li Y., Cheng H., Cui H. Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma. Chin. J. Cancer Res. 2015; 27(3): 309-17.
  37. Shen Y., Li L. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer. Tumour Biol. 2016; 37(11): 14765-72.
  38. Chudecka-Glaz A.M., Cymbaluk-Ploska A.A., Menkiszak J.L., Sompolska-Rzechula A.M., Toloczko-Grabarek A.I., Rzepka-Gorska I.A. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J. Ovarian Res. 2014; 7: 62.
  39. Pelissier A., Roulot A., Guery B., Bonneau C., Bellet D., Rouzier R. Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer. J. Ovarian Res. 2016; 9(1): 61.
  40. Brun J.L., Rouzier R., Selle F., Houry S., Uzan S., Darai E. Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy. BMC Cancer. 2009; 9: 171.
  41. Fagotti A., Vizzielli G., Fanfani F., Costantini B., Ferrandina G., Gallotta V. et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. Gynecol. Oncol. 2013; 131(2): 341-6.
  42. Fagotti A., Vizzielli G., De Iaco P., Surico D., Buda A., Mandato V.D. et al. A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am. J. Obstet. Gynecol. 2013; 209(5): 462 e1-462 e11.
  43. Rutten M.J., van Meurs H.S., van de Vrie R., Gaarenstroom K.N., Naaktgeboren C.A., van Gorp T. et al. Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial. J. Clin. Oncol. 2017; 35(6): 613-21.
  44. Fagotti A., Ferrandina G., Fanfani F., Ercoli A., Lorusso D., Rossi M. et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann. Surg. Oncol. 2006; 13(8): 1156-61.
  45. Petrillo M., Vizzielli G., Fanfani F., Gallotta V., Cosentino F., Chiantera V. et al. Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept. Gynecol. Oncol. 2015; 139(1): 5-9.
  46. Brun J.L., Rouzier R., Uzan S., Darai E. External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. Gynecol. Oncol. 2008; 110(3): 354-9.
  47. Aletti G.D., Eisenhauer E.L., Santillan A., Axtell A., Aletti G., Holschneider C. et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol. Oncol. 2011; 120(1): 23-8.
  48. Eoh K.J., Yoon J.W., Lee J.Y., Nam E.J., Kim S., Kim S.W. et al. A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy. BMC Cancer. 2017; 17(1): 481.
  49. Aletti G.D., Santillan A., Eisenhauer E.L., Hu J., Aletti G., Podratz K.C. et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol. Oncol. 2007; 107(1): 99-106.
  50. Eng K.H., Morrell K., Starbuck K., Spring-Robinson C., Khan A., Cleason D. et al. Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. Gynecol. Oncol. 2017; 146(1): 52-7.

版权所有 © Eco-Vector, 2017


 


##common.cookie##